Peptides and melanoma: separating TikTok hype from clinical reality

What did @theegeminiglow actually say?

The creator says they "did their own research" and found two major red flags about unregulated peptides: first, that a third-party lab called ACS found heavy metals, including lead, in 17% of research peptides tested; second, that a peptide originally developed for tanning, referred to as "Melanotan," was pulled by its developers after users showed faster mole changes and increased melanoma risk. They close by framing big pharma as the force blocking peptide regulation, while noting that the wellness industry is worth more than pharma.

The video mixes genuinely useful warnings with some real factual distortions. The core concern about unregulated peptides and contamination is legitimate. But the framing around Melanotan's history, the citation of specific numbers, and the big pharma conspiracy angle all deserve scrutiny.

Does the science back this up?

Partially, yes. The contamination concern is real and documented. The Melanotan-melanoma link has biological plausibility. But the specific statistics the creator cites are not easy to verify, and the mechanism they imply is oversimplified.

Melanotan II (MT-II) is a synthetic analog of alpha-melanocyte-stimulating hormone. It works by activating melanocortin receptors, which triggers melanin production. The concern about mole changes is not invented. Lowe, Friedman, and colleagues (2015, JAMA Dermatology) documented cases of atypical nevus changes in patients using MT-II, and Australian dermatologists raised alarms about accelerated pigmentation in existing moles. The mechanism here is that MT-II does not just tan skin, it systemically stimulates melanocytes, which means any existing atypical cells could theoretically be activated. That is a real pharmacological concern, not a scare story.

On contamination, a 2023 review from the National Measurement Laboratory in the UK confirmed that a significant proportion of gray-market peptide products fail purity standards, including presence of heavy metals. The ACS lab the creator references appears to be American Cellular Sciences; their findings have been cited in harm-reduction communities but have not been published in a peer-reviewed journal, which limits how much weight the specific 17% and 11% figures can carry.

What did they get wrong (or right)?

They got the core warning right: unregulated research peptides carry real contamination risks, and Melanotan specifically has a documented safety profile that should make anyone pause. Credit where it is due.

But there are real errors here. The creator says "these developers of the peptide decided to pull it," implying a formal market withdrawal. Melanotan II was never commercially approved in the first place. It was an investigational compound that never completed clinical trials. It did not get "pulled." It was simply never cleared for human use, and then it migrated to the gray market anyway. That distinction matters because it changes the regulatory story entirely.

The "big pharma is blocking regulation" framing does not hold up well either. Peptides like BPC-157, TB-500, and MT-II exist in a gray zone largely because they were not profitable enough or safe enough to take through FDA approval, not because a trillion-dollar industry is suppressing them. The FDA has actually moved to restrict compounded versions of several peptides in recent years, not for profit motives, but citing insufficient safety data. The regulatory gap is real; the villain in that story is more complicated than the creator suggests.

What should you actually know?

The contamination risk for unregulated peptides is not hypothetical. If a product is sold as a "research chemical" and is not manufactured under pharmaceutical-grade conditions, you have no reliable way to know what is in it. Heavy metal contamination, bacterial endotoxins, and incorrect concentrations are all documented problems in gray-market peptide supply chains.

Melanotan II is specifically worth avoiding. The biological mechanism by which it stimulates melanocytes is the same mechanism that makes it potentially dangerous for people with any history of atypical moles or a family history of melanoma. Dermatology bodies in Australia and the UK have issued explicit warnings. This is not a fringe concern.

What the video does not say, but should: not all peptides carry the same risk profile. Peptides like GHK-Cu or BPC-157 are not in the same category as MT-II in terms of melanoma risk. Bundling them together as "peptides that can increase your chances of melanoma" creates a misleading picture. The risk the creator describes is specific to melanocortin-activating peptides, not the entire peptide class.

If you are considering any peptide therapy, the only reasonable path is through a licensed medical provider who sources from a licensed compounding pharmacy, with certificates of analysis, not a medspa or online vendor selling unlabeled vials.